PE20141583A1 - Nuevos derivados de piridina - Google Patents

Nuevos derivados de piridina

Info

Publication number
PE20141583A1
PE20141583A1 PE2013002773A PE2013002773A PE20141583A1 PE 20141583 A1 PE20141583 A1 PE 20141583A1 PE 2013002773 A PE2013002773 A PE 2013002773A PE 2013002773 A PE2013002773 A PE 2013002773A PE 20141583 A1 PE20141583 A1 PE 20141583A1
Authority
PE
Peru
Prior art keywords
methyl
pyridine derivatives
cycloalkyl
refers
propanoate
Prior art date
Application number
PE2013002773A
Other languages
English (en)
Inventor
Caterina Bissantz
Uwe Grether
Atsushi Kimbara
Qingping Liu
Matthias Nettekoven
Marco Prunottto
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Christoph Ullmer
Zhiwei Wang
Wulun Yang
Paul Hebeisen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20141583A1 publication Critical patent/PE20141583A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE LA FORMULA (I), EN LA QUE R1 ES CICLOALQUILO, CICLOALQUILALCOXI, HALOALCOXI, FENILALCOXI, ENTRE OTROS; R2 ES H, HALOGENO, ALQUILO, HALOALQUILO, CICLOALQUILO, ENTRE OTROS; R3 Y R4 JUNTO CON EL ATOMO DE NITROGENO AL QUE ESTAN UNIDOS FORMAN UN PIPERIDINILO, 1,1-DIOXIDOTETRAHIDRO-2H-TIO-PIRANILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-METIL-2-(5-METIL-6-(2,2,2-TRIFLUORETOXI)PICOLINAMIDO)-PROPANOATO DE METILO, 2-[(6-CICLOHEXIL-PIRIDINA-2-CARBONIL)-AMINO]-2-METIL-PROPANOATO DE METILO, ENTRE OTROS. SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS, ISQUEMIA, ENTRE OTROS.
PE2013002773A 2011-06-10 2012-06-07 Nuevos derivados de piridina PE20141583A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011075606 2011-06-10

Publications (1)

Publication Number Publication Date
PE20141583A1 true PE20141583A1 (es) 2014-10-25

Family

ID=46208600

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2017002309A PE20180037A1 (es) 2011-06-10 2012-06-07 Nuevos derivados de piridina
PE2013002773A PE20141583A1 (es) 2011-06-10 2012-06-07 Nuevos derivados de piridina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2017002309A PE20180037A1 (es) 2011-06-10 2012-06-07 Nuevos derivados de piridina

Country Status (36)

Country Link
US (2) US9321727B2 (es)
EP (2) EP2718266B9 (es)
JP (3) JP5997265B2 (es)
KR (1) KR20140042848A (es)
CN (2) CN103608332B (es)
AR (1) AR086881A1 (es)
AU (2) AU2012266369B2 (es)
BR (1) BR112013031463A2 (es)
CA (1) CA2835745A1 (es)
CL (1) CL2013003486A1 (es)
CO (1) CO6811864A2 (es)
CR (1) CR20130616A (es)
CY (1) CY1117878T1 (es)
DK (2) DK2718266T3 (es)
EA (2) EA027247B1 (es)
EC (1) ECSP13013074A (es)
ES (2) ES2588327T3 (es)
HK (1) HK1231465A1 (es)
HR (2) HRP20161064T2 (es)
HU (2) HUE037666T2 (es)
IL (2) IL229685B (es)
LT (1) LT3072886T (es)
MA (1) MA35245B1 (es)
MX (1) MX339992B (es)
MY (1) MY184978A (es)
PE (2) PE20180037A1 (es)
PH (1) PH12016501375A1 (es)
PL (2) PL2718266T3 (es)
PT (2) PT2718266T (es)
RS (2) RS55073B9 (es)
SG (1) SG10201604687QA (es)
SI (2) SI2718266T1 (es)
TR (1) TR201808273T4 (es)
TW (1) TWI567062B (es)
UA (1) UA114087C2 (es)
WO (1) WO2012168350A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
MY179412A (en) 2012-12-07 2020-11-05 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists
WO2014086705A1 (en) * 2012-12-07 2014-06-12 F. Hoffmann-La Roche Ag Novel pyridine derivatives
LT2928868T (lt) * 2012-12-07 2017-10-25 F. Hoffmann-La Roche Ag Piridin-2-amidai, tinkami naudoti kaip cb2 agonistai
LT2928882T (lt) 2012-12-07 2017-03-27 F. Hoffmann-La Roche Ag Pirazino dariniai kaip cb2 receptoriaus agonistai
ES2629751T3 (es) 2013-03-07 2017-08-14 F. Hoffmann-La Roche Ag Derivados de pirazol novedosos
EA027569B1 (ru) * 2013-03-26 2017-08-31 Ф.Хоффманн-Ля Рош Аг Производные пиридина
UA116801C2 (uk) 2013-05-02 2018-05-10 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2
RS57461B1 (sr) 2013-05-02 2018-09-28 Hoffmann La Roche Derivati purina kao agonisti cb2 receptora
MX2016008688A (es) * 2013-12-30 2017-01-12 Lifesci Pharmaceuticals Inc Compuestos terapéuticos inhibidores.
SG11201608108SA (en) * 2014-04-04 2016-10-28 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists
PE20161407A1 (es) * 2014-04-04 2016-12-28 Hoffmann La Roche Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide
CN104004006B (zh) * 2014-05-15 2016-04-06 广州康瑞泰药业有限公司 一种3,6-二氢-2h-吡喃-4-硼酸频哪醇酯的合成方法
CN104003934B (zh) * 2014-06-13 2016-04-13 西华大学 6-氯-3-氟-2-吡啶甲酸的合成
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
HUE061437T2 (hu) 2015-10-23 2023-06-28 Navitor Pharm Inc A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai
EP3380455A1 (en) * 2015-11-26 2018-10-03 H. Hoffnabb-La Roche Ag Trypanosomes inhibitors
CA2999216A1 (en) * 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Phenyl derivatives as cannabinoid receptor 2 agonists
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
AR110770A1 (es) 2017-01-23 2019-05-02 Cadent Therapeutics Inc Moduladores del canal de potasio
WO2018200625A1 (en) * 2017-04-26 2018-11-01 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
WO2018234284A1 (en) 2017-06-20 2018-12-27 F. Hoffmann-La Roche Ag PYRIDINE DERIVATIVES
WO2020002270A1 (en) * 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
WO2020002280A1 (en) * 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
SG11202009103WA (en) * 2018-06-27 2020-10-29 Hoffmann La Roche Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
AU2019366312A1 (en) 2018-10-22 2021-05-20 Novartis Ag Crystalline forms of potassium channel modulators
CA3117336A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1
CN109665982B (zh) * 2019-01-22 2022-07-08 深圳市第二人民医院 奈非西坦中间体2-吡咯烷酮的合成方法
US11723890B2 (en) 2019-11-01 2023-08-15 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
MX2022011813A (es) * 2020-03-23 2022-11-14 Praxis Prec Medicines Inc Inhibidores de kcnt1 y metodos de uso.
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2022272062A1 (en) * 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Ep2 antagonist compounds
WO2023169984A1 (en) * 2022-03-11 2023-09-14 Syngenta Crop Protection Ag Herbicidal compounds
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005965D0 (en) 1990-03-16 1990-05-09 Shell Int Research Herbicidal carboxamide derivatives
GB9025828D0 (en) * 1990-11-28 1991-01-09 Shell Int Research Herbicidal carboxamide derivatives
TW204343B (es) * 1991-05-31 1993-04-21 Sumitomo Pharmaceutics Co Ltd
TW226012B (es) * 1991-11-19 1994-07-01 Dunlena Pty Ltd
GB2277930A (en) 1993-05-11 1994-11-16 Shell Int Research Herbicidal picolinamide derivatives
US7271266B2 (en) * 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
WO2004014844A2 (en) 2002-08-09 2004-02-19 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
WO2005079802A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
WO2006009134A1 (ja) * 2004-07-21 2006-01-26 Mitsui Chemicals, Inc. ジアミン誘導体、その製造方法およびそれらを有効成分とする殺菌剤
WO2006106054A1 (en) * 2005-04-06 2006-10-12 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
DE602007006019D1 (de) 2006-06-28 2010-06-02 Glaxo Group Ltd Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate
CN101516839A (zh) * 2006-09-25 2009-08-26 贝林格尔.英格海姆国际有限公司 调节cb2受体的化合物
ES2344128T3 (es) * 2006-10-04 2010-08-18 F. Hoffmann-La Roche Ag Derivados de pirazina-2-carboxamida como moduladores de receptores cb2.
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
SE535157C2 (sv) * 2010-07-14 2012-05-02 Fairchild Semiconductor Konduktivitetsmodulering i en bipolär transistor i kiselkarbid
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor

Also Published As

Publication number Publication date
AU2012266369A1 (en) 2013-11-21
MA35245B1 (fr) 2014-07-03
MY184978A (en) 2021-04-30
PL2718266T3 (pl) 2016-11-30
HRP20180897T1 (hr) 2018-07-13
US9321727B2 (en) 2016-04-26
AU2012266369B2 (en) 2016-11-10
PT2718266T (pt) 2016-07-11
CA2835745A1 (en) 2012-12-13
CN103608332A (zh) 2014-02-26
JP6484746B2 (ja) 2019-03-13
MX339992B (es) 2016-06-21
RS57262B1 (sr) 2018-08-31
CY1117878T1 (el) 2017-05-17
SI2718266T1 (sl) 2016-08-31
EA201591527A1 (ru) 2016-04-29
DK2718266T3 (en) 2016-06-13
PH12016501375A1 (en) 2017-12-11
AU2017200801A1 (en) 2017-03-02
JP2017031162A (ja) 2017-02-09
SG10201604687QA (en) 2016-07-28
MX2013014564A (es) 2014-03-21
EA027247B1 (ru) 2017-07-31
EP2718266B1 (en) 2016-05-25
KR20140042848A (ko) 2014-04-07
TW201311645A (zh) 2013-03-16
NZ617464A (en) 2016-01-29
AU2017200801B2 (en) 2018-11-22
PT3072886T (pt) 2018-06-12
HRP20161064T2 (hr) 2017-02-24
ES2588327T3 (es) 2016-11-02
CN106349156A (zh) 2017-01-25
JP2014516071A (ja) 2014-07-07
PL3072886T3 (pl) 2018-08-31
UA114087C2 (xx) 2017-04-25
SI3072886T1 (en) 2018-07-31
US20120316147A1 (en) 2012-12-13
JP5997265B2 (ja) 2016-09-28
BR112013031463A2 (pt) 2016-12-06
TR201808273T4 (tr) 2018-07-23
IL256826B (en) 2018-08-30
EP3072886B1 (en) 2018-04-18
NZ715284A (en) 2017-06-30
HRP20161064T1 (hr) 2016-10-21
CO6811864A2 (es) 2013-12-16
EA023287B1 (ru) 2016-05-31
EA201391822A1 (ru) 2014-05-30
LT3072886T (lt) 2018-07-10
PE20180037A1 (es) 2018-01-09
CN103608332B (zh) 2016-09-28
ES2588327T9 (es) 2017-02-21
IL229685A0 (en) 2014-01-30
HK1231465A1 (zh) 2017-12-22
RS55073B9 (sr) 2019-07-31
EP2718266A1 (en) 2014-04-16
JP6349360B2 (ja) 2018-06-27
ES2673614T3 (es) 2018-06-25
CN106349156B (zh) 2018-12-11
EP2718266B9 (en) 2016-11-30
AR086881A1 (es) 2014-01-29
HUE027669T2 (en) 2016-11-28
RS55073B1 (sr) 2016-12-30
US20160137606A1 (en) 2016-05-19
WO2012168350A1 (en) 2012-12-13
HUE037666T2 (hu) 2018-09-28
JP2018150367A (ja) 2018-09-27
TWI567062B (zh) 2017-01-21
EP3072886A1 (en) 2016-09-28
IL229685B (en) 2018-02-28
CL2013003486A1 (es) 2014-11-03
DK3072886T3 (en) 2018-06-25
ECSP13013074A (es) 2014-01-31
CR20130616A (es) 2018-01-26

Similar Documents

Publication Publication Date Title
PE20141583A1 (es) Nuevos derivados de piridina
PE20141691A1 (es) Compuestos con actividad nematicida
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
RS54445B1 (en) 3,5-DIAMINO-6-CHLORO-N- (N- (4- (4- (2- (HEXYL (2,3,4,5,6-PENTAHYDROXYHEXYL) AMINO) ETHOXY) PHENYL) BUTYL) CARBAMIMIDOIL) PYRAZINE -2-CARBOXAMIDE
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
EA201491079A1 (ru) Арил дигидропиридиноновые и пиперидиноновые ингибиторы mgat2
CO7350620A2 (es) Nuevos derivados de piridina
AR087311A1 (es) Quinolinas sustituidas y su uso como medicamentos
CR20130369A (es) Novedosos derivados heterocíclicos
AR059494A1 (es) Derivados biciclicos de bisamida con actividad pesticida
RS54492B1 (en) KINASE INHIBITOR REGULATING THE SIGNAL PATH OF APOPTOSIS
RS54653B1 (en) 2- (2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT
PE20141698A1 (es) Proceso para la preparacion de derivados de l-alanina protegidos
EA201390934A1 (ru) Композиции и способы модулирования fxr
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
PE20191142A1 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
EA201590296A1 (ru) Дейтерированный ибрутиниб
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR083903A1 (es) Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
PE20142282A1 (es) Nuevos derivados de aril-quinolina
EA201201082A1 (ru) Фармацевтическая композиция, содержащая n-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамид
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2

Legal Events

Date Code Title Description
FG Grant, registration